REXULTI® (Brexpiprazole) FDA Approved for Treating Agitation in Alzheimer's Disease Patients

REXULTI® (brexpiprazole) has been approved by the FDA for treating agitation associated with dementia due to Alzheimer's disease, making it the first and only pharmacological treatment for this indication in the US.

FDA Approves First Drug to Treat Agitation Symptoms Associated

FDA Approves First Drug to Treat Agitation Symptoms Associated

FDA AdCom votes in favour of Lundbeck's/Otsuka's Rexulti in AAD

JAMA Neurology Publishes Complete Results of Positive Phase 3

Otsuka and Lundbeck Issue Statement on FDA Advisory Committee

FDA Accepts sNDA for Rexulti for Alzheimer's Agitation

Lundbeck and Otsuka await important exam results on Friday for

FDA Approves the First Drug for Alzheimer's Agitation: Rexulti

Brexpiprazole For Alzheimer's Agitation - Is The Juice Worth The

Otsuka, Lundbeck's sNDA for Rexulti received US FDA approval

SLU Researcher Finds Help for Alzheimer's-Associated Agitation

Antipsychotic Drug Reduces Alzheimer's-Associated Agitation

Pyrls on Instagram: Brexpiprazole's (REXULTI) new indication

FDA Approves First Drug to Treat Alzheimer's Agitation

FDA approves Rexulti for agitation tied to Alzheimer's dementia